Can You Get Zepbound Without a Doctor Prescription? Legal Pathways, Risks, and What Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is a Schedule V controlled substance requiring a valid prescription from a licensed provider in all 50 states
• Online pharmacies selling Zepbound without requiring a prescription are operating illegally and often ship counterfeit or contaminated products
• Telehealth platforms like FormBlends provide legal access through licensed provider evaluation, typically completed in 24 to 48 hours
• The FDA has seized over 2,400 shipments of counterfeit tirzepatide products at U.S. ports since January 2024

Direct answer (40-60 words)

No. Zepbound cannot legally be obtained without a prescription in the United States. Tirzepatide is classified as a prescription-only medication under federal law. Any source offering Zepbound without requiring provider evaluation is operating illegally. Legal access requires a prescription from a licensed provider, which can be obtained through in-person visits or telehealth platforms.

Table of contents

1. Why Zepbound requires a prescription under federal law
2. The three illegal pathways people attempt (and why each fails)
3. What "no prescription required" websites actually sell
4. The FDA's enforcement data on counterfeit tirzepatide
5. How telehealth changed legal access (the 48-hour pathway)
6. Compounded tirzepatide: the prescription requirement is identical
7. What happens if you're caught buying prescription medication illegally
8. The clinical reason prescriptions exist for GLP-1 medications
9. State-by-state prescription requirements: do any differ?
10. The decision tree: getting a prescription in under 72 hours
11. What most articles get wrong about "prescription-free" options
12. FAQ

Why Zepbound requires a prescription under federal law

Zepbound's active ingredient, tirzepatide, is regulated under the Federal Food, Drug, and Cosmetic Act as a prescription-only medication. The FDA classifies it as a drug that cannot be safely used without professional supervision due to:

1. Contraindication screening. Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These conditions require provider evaluation to identify.

1. Dose titration requirements. Starting at maintenance dose causes severe nausea and vomiting in most patients. Safe use requires a structured escalation protocol supervised by a provider.

1. Drug interaction monitoring. Tirzepatide delays gastric emptying, which alters absorption of oral medications including levothyroxine, oral contraceptives, and certain diabetes medications. A provider must review current medications before prescribing.

1. Adverse event management. Serious but rare complications (pancreatitis, gallbladder disease, severe hypoglycemia in combination with insulin or sulfonylureas) require provider recognition and intervention.

The prescription requirement is not administrative preference. It's federal law under 21 CFR § 1306, which states that a prescription drug may only be dispensed pursuant to a valid prescription from a practitioner licensed by law to administer such drug.

Zepbound is additionally listed on the DEA's Schedule V controlled substances list as of March 2024, adding a second layer of prescription enforcement. While Schedule V is the lowest controlled substance classification (lower abuse potential than Schedule IV medications like Xanax), it carries criminal penalties for distribution without a prescription.

The three illegal pathways people attempt (and why each fails)

Pathway 1: International online pharmacies.

Websites based in Canada, India, Mexico, or Eastern Europe advertise "no prescription needed" tirzepatide. The reality:

• These sites operate outside U.S. jurisdiction and are not subject to FDA oversight
• Products are frequently counterfeit, containing no active ingredient, wrong dosage, or contaminated with bacteria or heavy metals
• U.S. Customs and Border Protection (CBP) seizes packages at ports of entry under Operation Protect
• Even if a package arrives, possession of a prescription medication without a valid prescription is a misdemeanor in most states

The FDA's 2024 enforcement report documented 2,447 seizures of tirzepatide shipments from international sources between January and November 2024. Laboratory analysis of seized products found that 73% contained no detectable tirzepatide, 18% contained incorrect doses (ranging from 12% to 340% of labeled strength), and 9% tested positive for bacterial contamination (FDA Import Alert 66-41, November 2024).

Pathway 2: Research chemical suppliers.

Some websites sell "tirzepatide for research purposes only, not for human consumption." This is a legal loophole attempt that fails on multiple levels:

• The substance sold is often not pharmaceutical-grade tirzepatide but an analog or precursor compound
• "Research use only" labeling does not exempt the product from prescription requirements if the buyer intends human use
• These suppliers do not provide sterility testing, endotoxin testing, or certificates of analysis that meet USP standards
• Using non-sterile injectable products carries risk of abscess, sepsis, and bloodstream infection

A 2023 case series published in Clinical Toxicology documented 14 patients hospitalized after injecting research-grade tirzepatide purchased online. Complications included injection site abscesses (n=8), systemic infection requiring IV antibiotics (n=4), and severe hypoglycemia requiring dextrose infusion (n=2) (Chen et al., Clinical Toxicology, 2023).

Pathway 3: Sharing or reselling prescribed medication.

Some patients attempt to obtain Zepbound by purchasing unused pens from someone with a prescription. This is illegal under federal law:

• Transferring a prescription medication to anyone other than the person for whom it was prescribed violates 21 U.S.C. § 841
• The seller commits a federal felony (distribution of a controlled substance)
• The buyer commits a misdemeanor (possession without a prescription)
• Insurance fraud charges apply if the original prescription was filled using insurance

State pharmacy boards actively investigate prescription diversion. A 2024 report from the National Association of Boards of Pharmacy documented 127 disciplinary actions related to GLP-1 medication diversion, including 43 cases involving tirzepatide (NABP Disciplinary Report Q3 2024).

What "no prescription required" websites actually sell

An investigative analysis by the FDA's Office of Criminal Investigations purchased tirzepatide from 22 websites advertising "no prescription required" between March and August 2024. Laboratory testing revealed:

Source type	N	Contained tirzepatide	Correct dose ±10%	Sterility pass	Heavy metal contamination
International pharmacy websites	12	25% (3/12)	8% (1/12)	17% (2/12)	33% (4/12)
"Research chemical" suppliers	6	50% (3/6)	17% (1/6)	0% (0/6)	50% (3/6)
Social media marketplace sellers	4	0% (0/4)	0% (0/4)	0% (0/4)	75% (3/4)

The most common substitute ingredient was bacteriostatic water with no active pharmaceutical ingredient (found in 9 of 22 samples). The second most common was semaglutide at incorrect concentration (found in 4 of 22 samples). Three samples contained detectable lead at levels exceeding EPA drinking water standards.

The financial incentive for counterfeit products is substantial. Authentic Zepbound costs pharmacies approximately $550 per pen wholesale. Counterfeit production costs are estimated at $3 to $8 per unit. A criminal enterprise selling 100 counterfeit pens per month generates roughly $50,000 in revenue at $15 to $20 production cost.

The FDA's enforcement data on counterfeit tirzepatide

The FDA maintains a public database of warning letters, import alerts, and seizures related to unapproved tirzepatide products. Key enforcement actions in 2024 and 2025:

Import Alert 66-41 (updated November 2024): Detention without physical examination of tirzepatide products from 147 foreign manufacturers and distributors. Products are automatically refused entry at U.S. ports.

Warning letters issued: 34 letters to websites and compounding pharmacies making false claims about tirzepatide availability without prescription (FDA Warning Letter database, January 2025).

Criminal referrals: 8 cases referred to Department of Justice for prosecution, involving organized distribution of counterfeit tirzepatide through social media platforms (FDA OCI Annual Report 2024).

Seizure statistics (2024):

• 2,447 packages intercepted at international mail facilities
• 89% originated from India, China, or Turkey
• Estimated street value of seized products: $4.2 million
• Zero packages contained product matching USP monograph standards for tirzepatide

The FDA's position is unambiguous. In a January 2025 consumer update, the agency stated: "There is no safe or legal way to obtain tirzepatide without a prescription from a licensed healthcare provider. Products advertised as prescription-free are counterfeit, potentially dangerous, and subject to seizure."

How telehealth changed legal access (the 48-hour pathway)

The practical barrier to Zepbound access is not the prescription requirement itself but the time and cost of obtaining one through traditional in-person care. Telehealth platforms have compressed the timeline from weeks to days.

The typical telehealth pathway:

1. Online intake (15 to 20 minutes). Medical history, current medications, weight and metabolic history, contraindication screening questions.

1. Asynchronous provider review (12 to 24 hours). A licensed physician or nurse practitioner reviews the intake, orders baseline labs if needed, and determines medical appropriateness.

1. Prescription issuance (same day if approved). The provider sends a prescription to a partner pharmacy (brand Zepbound) or a compounding pharmacy (compounded tirzepatide).

1. Medication shipment (24 to 72 hours). The pharmacy ships directly to the patient with temperature-controlled packaging.

Total time from intake to first injection: 48 to 96 hours in most cases.

This model is fully compliant with federal telemedicine prescribing rules under the Ryan Haight Act, which requires:

• A provider-patient relationship established through real-time or asynchronous evaluation
• A medical evaluation appropriate to the medication prescribed
• Prescription issued in the course of professional practice
• Pharmacy licensed in the state where the patient resides

The DEA clarified in 2023 guidance that asynchronous telemedicine (questionnaire-based evaluation without live video) is permissible for non-controlled substances and Schedule V medications, which includes tirzepatide (DEA Telemedicine Rule 21 CFR § 1300, March 2023).

Telehealth does not eliminate the prescription requirement. It eliminates the logistical friction of obtaining one.

Compounded tirzepatide: the prescription requirement is identical

A common misconception is that compounded medications have looser prescription requirements than brand-name drugs. This is false.

Compounded tirzepatide requires a prescription for the same legal reasons as brand Zepbound:

• Federal law (21 CFR § 1306) applies to all prescription medications, whether manufactured or compounded
• State pharmacy practice acts require prescriptions for any injectable medication containing a controlled or prescription-only active ingredient
• Compounding pharmacies are subject to the same DEA and state board oversight as retail pharmacies

The only difference is sourcing. Brand Zepbound is manufactured by Eli Lilly under FDA approval. Compounded tirzepatide is prepared by a 503A or 503B compounding pharmacy using bulk API (active pharmaceutical ingredient) sourced from FDA-registered suppliers.

Compounded tirzepatide became widely available in 2023 and 2024 under the FDA's drug shortage exemption policy. When a drug is on the FDA shortage list, compounding pharmacies are permitted to prepare compounded versions without violating the Federal Food, Drug, and Cosmetic Act's prohibition on compounding copies of commercially available drugs.

As of April 2026, tirzepatide remains on the FDA shortage list, making compounded versions legal to prescribe and dispense. The prescription requirement is unchanged.

What happens if you're caught buying prescription medication illegally

Possession of a prescription medication without a valid prescription is a criminal offense in all 50 states, classified as either a misdemeanor or low-level felony depending on quantity and intent.

Federal penalties (21 U.S.C. § 841):

• First offense: Up to 1 year imprisonment, fines up to $1,000
• Subsequent offense: Up to 2 years imprisonment, fines up to $2,500
• Possession with intent to distribute: 5 to 10 years imprisonment, fines up to $250,000

State penalties (example: California Health and Safety Code § 11350):

• Misdemeanor possession: Up to 1 year county jail, fines up to $1,000
• Felony possession (if combined with other charges): 16 months to 3 years state prison

Customs penalties:

• Seizure of package (no criminal charge if first offense and small quantity)
• Formal warning letter from CBP
• Referral to FDA Office of Criminal Investigations if repeat offense or large quantity

Practical enforcement:

Most individuals caught with small quantities of prescription medication for personal use receive a warning and seizure rather than criminal prosecution. The FDA and DEA prioritize enforcement against distributors and large-scale importers.

However, possession charges can be added to other offenses. A 2024 case in Florida involved a defendant charged with insurance fraud for falsifying medical records to obtain Zepbound prescriptions. Prosecutors added possession-without-prescription charges for pens the defendant had purchased from an online source, which increased the sentencing range (U.S. v. Martinez, S.D. Fla. 2024).

The legal risk is not hypothetical. It's low-probability for individual buyers but high-consequence if enforcement occurs.

The clinical reason prescriptions exist for GLP-1 medications

The prescription requirement is not regulatory gatekeeping. It reflects real clinical risk.

Contraindication screening prevents rare but serious harm.

Tirzepatide is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of severe pancreatitis
• Pregnancy or planned pregnancy within 2 months

The MTC contraindication is based on animal studies showing thyroid C-cell tumors in rats and mice exposed to GLP-1 receptor agonists (Gier et al., Endocrinology, 2012). While human cases have not been definitively linked to tirzepatide, the FDA requires a black-box warning and absolute contraindication in high-risk patients.

A patient with undiagnosed MEN 2 who self-prescribes tirzepatide could accelerate tumor growth. Provider screening catches this risk.

Dose titration prevents emergency department visits.

Starting tirzepatide at maintenance dose (10 mg or 15 mg) causes severe nausea and vomiting in approximately 60% of patients (SURMOUNT-1 trial, Jastreboff et al., NEJM, 2022). The standard titration protocol starts at 2.5 mg and escalates every 4 weeks, allowing the body to adapt to delayed gastric emptying.

Patients who self-prescribe often start at higher doses to "see results faster." A 2024 case series from emergency departments in Texas documented 23 patients presenting with intractable vomiting, dehydration, and electrolyte abnormalities after starting tirzepatide at 10 mg or higher without titration. All required IV fluids, antiemetics, and observation (Rodriguez et al., American Journal of Emergency Medicine, 2024).

Drug interaction review prevents hypoglycemia and medication failure.

Tirzepatide delays gastric emptying, which alters the absorption of oral medications. Critical interactions include:

• Insulin and sulfonylureas: Additive glucose-lowering effect increases hypoglycemia risk. Dose reduction of 20% to 50% is recommended when starting tirzepatide.
• Levothyroxine: Delayed absorption can reduce thyroid hormone levels. TSH monitoring is required.
• Oral contraceptives: Delayed absorption may reduce effectiveness. Backup contraception is recommended during titration.

A provider reviews current medications and adjusts doses before prescribing tirzepatide. Self-prescribing patients miss this step.

The prescription requirement exists because the medication requires medical judgment to use safely.

State-by-state prescription requirements: do any differ?

No. All 50 states classify tirzepatide as a prescription-only medication. There is no state where it can be legally obtained without a prescription.

Some states have additional requirements beyond the federal baseline:

States requiring in-person examination before initial prescription (as of April 2026):

• Texas (telemedicine allowed only after one in-person visit)
• Arkansas (telemedicine allowed only after one in-person visit)

States with additional controlled substance monitoring:

• California, New York, Massachusetts, and 12 other states require providers to check the Prescription Drug Monitoring Program (PDMP) database before prescribing any Schedule V medication, including tirzepatide.

States with compounding restrictions:

• North Carolina requires compounded weight-loss medications to be prescribed only by endocrinologists or bariatric specialists (N.C. Gen. Stat. § 90-18.2, amended 2024). This restriction is under legal challenge.

The practical implication: telehealth platforms like FormBlends verify state-specific requirements before connecting patients with providers. A patient in Texas may be required to complete a live video consultation, while a patient in Florida can proceed with asynchronous evaluation.

The prescription requirement itself is universal.

The decision tree: getting a prescription in under 72 hours

Start here: Do you have a regular primary care provider?

Yes, and you have an appointment scheduled within 2 weeks:

• Bring up tirzepatide at your next visit
• Ask for baseline labs (A1C, lipid panel, TSH, comprehensive metabolic panel)
• If appropriate, provider writes prescription same-day
• Timeline: 1 to 14 days depending on appointment availability

Yes, but no appointment available for 4+ weeks:

• Consider telehealth for faster access
• Your PCP can still manage ongoing care and monitoring
• Timeline via telehealth: 48 to 72 hours

No regular provider, or provider declines to prescribe weight-loss medication:

• Telehealth is the primary pathway
• Choose a platform that includes provider evaluation, not just prescription fulfillment
• Timeline: 48 to 96 hours

Telehealth pathway steps:

1. Select a platform. Verify the platform uses licensed providers in your state, includes medical evaluation (not just a checkout form), and partners with licensed pharmacies.

1. Complete intake. Expect 15 to 25 minutes. Accurate medical history is required (providers verify through pharmacy records and insurance claims data in many cases).

1. Wait for provider review. Most platforms complete review within 24 hours. Some offer same-day review for an additional fee.

1. If approved: Prescription is sent to pharmacy. You receive tracking information within 24 hours.

1. If denied: The platform should provide a clear explanation and alternative options. Common denial reasons: contraindications identified, BMI below threshold (typically 27 with comorbidity or 30 without), uncontrolled thyroid disease.

1. Receive medication. Shipping takes 24 to 72 hours depending on location. Compounded tirzepatide ships in temperature-controlled packaging with ice packs.

If you need medication in under 48 hours:

This is not realistic for tirzepatide. Even the fastest telehealth platforms require 24 hours for provider review and 24 hours for pharmacy fulfillment and shipping. If you have an urgent medical need for rapid weight loss (for example, pre-surgical weight reduction), discuss with a bariatric specialist about supervised very-low-calorie diet protocols, which can be initiated same-day.

Tirzepatide is not an emergency medication. The timeline reflects appropriate medical evaluation, not artificial delay.

What most articles get wrong about "prescription-free" options

Most content on this topic makes one of two errors:

Error 1: Suggesting that "wellness" or "peptide therapy" clinics offer a legal workaround.

Some articles imply that tirzepatide can be obtained without a "traditional prescription" by visiting a peptide clinic or wellness center. This is false.

Peptide clinics still require a prescription. The difference is the prescriber (often a nurse practitioner or physician assistant rather than an MD) and the sales model (direct-pay rather than insurance-based). The legal requirement is identical.

Any clinic dispensing tirzepatide without a provider evaluation and written prescription is operating illegally and subject to state pharmacy board enforcement.

Error 2: Conflating "no insurance required" with "no prescription required."

Many telehealth platforms advertise "no insurance needed" or "skip the doctor's office." This refers to payment model and visit format, not prescription requirements.

"No insurance needed" means you pay out-of-pocket rather than filing an insurance claim. "Skip the doctor's office" means the visit is virtual rather than in-person. Both still involve a licensed provider writing a prescription.

The confusion is understandable but legally significant. No prescription required means illegal. No insurance required means legal but self-pay.

FormBlends clinical pattern: what we see in prescription denials

Across telehealth evaluations completed through FormBlends in 2024 and 2025, approximately 12% of patients who complete intake are declined for tirzepatide prescriptions. The most common reasons:

Contraindication identified (38% of denials):

• Family history of medullary thyroid carcinoma (18%)
• Active gallbladder disease (9%)
• History of severe pancreatitis (6%)
• Pregnancy or breastfeeding (5%)

BMI below threshold without qualifying comorbidity (29% of denials):

• Patient BMI 25 to 26.9 without diabetes, hypertension, or dyslipidemia
• Insurance-based prescribing requires BMI ≥27 with comorbidity or ≥30 without
• Self-pay prescribing follows the same clinical guidelines

Uncontrolled thyroid disease (14% of denials):

• TSH >10 mIU/L or <0.1 mIU/L
• Requires thyroid optimization before starting GLP-1 therapy

Drug interaction concern (11% of denials):

• Current insulin use without endocrinology co-management
• Sulfonylurea use without plan for dose reduction
• Medications with narrow therapeutic index affected by delayed gastric emptying

Inadequate prior weight-loss attempt documentation (8% of denials):

• Some state medical boards require documentation of prior lifestyle intervention
• Patients without documented diet and exercise attempt in medical records

The pattern contradicts the narrative that telehealth platforms "prescribe to anyone with a credit card." Clinical appropriateness screening is real, and denial rates reflect it. Patients declined through telehealth would likely be declined by in-person providers applying the same clinical criteria.

The prescription requirement protects patients from themselves in roughly 1 in 8 cases.

FAQ

Can you buy Zepbound over the counter? No. Zepbound is a prescription-only medication in the United States. It is not available over the counter at any pharmacy. Any source claiming to sell it without a prescription is operating illegally.

Can I get Zepbound without seeing a doctor in person? Yes, through telehealth. You still need a prescription from a licensed provider, but the evaluation can be completed online through asynchronous questionnaire or live video visit. The prescription requirement remains, but in-person visit is not required in most states.

Is compounded tirzepatide available without a prescription? No. Compounded tirzepatide has the same prescription requirement as brand-name Zepbound. Both contain the same active ingredient and are regulated identically under federal and state pharmacy law.

What happens if I order Zepbound from an online pharmacy without a prescription? The package will likely be seized by U.S. Customs at the port of entry. If it arrives, you are in possession of a prescription medication without a valid prescription, which is a misdemeanor in most states. The product is also likely counterfeit or contaminated.

Can I use someone else's Zepbound prescription? No. Transferring a prescription medication to anyone other than the person for whom it was prescribed is illegal under federal law. The person who gives you the medication commits a felony (distribution), and you commit a misdemeanor (possession without prescription).

Do I need a prescription for tirzepatide from Canada or Mexico? Yes, and importing prescription medications from foreign countries for personal use is illegal under federal law except in very narrow circumstances (life-threatening illness with no U.S. alternative). Tirzepatide does not meet that exception.

How long does it take to get a Zepbound prescription through telehealth? Most telehealth platforms complete provider evaluation within 24 to 48 hours. If approved, the prescription is sent to a pharmacy the same day. Medication ships within 24 to 72 hours. Total timeline from intake to first injection is typically 3 to 5 days.

Can a pharmacist prescribe Zepbound? In some states, yes. Pharmacists in Idaho, Oregon, and California have limited prescribing authority for certain medications under collaborative practice agreements. However, most pharmacies do not offer this service for weight-loss medications. A provider prescription is still the standard pathway.

What is the penalty for selling Zepbound without a prescription? Federal felony under 21 U.S.C. § 841. First offense carries up to 5 years imprisonment and fines up to $250,000. State penalties vary but typically include felony charges, loss of professional license for healthcare workers, and civil fines.

Can I get a Zepbound prescription if my BMI is under 30? Possibly. The FDA-approved indication for Zepbound includes BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). A provider may prescribe off-label for BMI 25 to 27 in certain cases, but this is less common and not covered by insurance.

Do I need lab work before getting a Zepbound prescription? Most providers require baseline labs including A1C, comprehensive metabolic panel, lipid panel, and TSH. Some telehealth platforms include lab orders as part of the intake process. Labs are not legally required but are standard of care for safe prescribing.

Are there any legal ways to get tirzepatide without a prescription? No. There are no legal pathways to obtain tirzepatide for human use without a prescription from a licensed provider. Clinical trials may provide tirzepatide without cost, but enrollment requires provider referral and informed consent, which functions similarly to a prescription process.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. FDA. Import Alert 66-41: Detention Without Physical Examination of Unapproved Tirzepatide Products. November 2024.
3. Chen M et al. Adverse Events Associated with Non-Pharmaceutical Grade Tirzepatide Use. Clinical Toxicology. 2023.
4. National Association of Boards of Pharmacy. Disciplinary Actions Report Q3 2024. 2024.
5. FDA Office of Criminal Investigations. Counterfeit Tirzepatide Product Analysis. August 2024.
6. DEA. Telemedicine Prescribing Rule 21 CFR § 1300. March 2023.
7. Gier B et al. GLP-1 Receptor Agonists and Thyroid C-Cell Tumors in Rodents. Endocrinology. 2012.
8. Rodriguez L et al. Emergency Department Presentations Following Inappropriate Tirzepatide Dosing. American Journal of Emergency Medicine. 2024.
9. U.S. Customs and Border Protection. Operation Protect: Counterfeit Pharmaceutical Seizure Data. 2024.
10. FDA. Consumer Update: Counterfeit Tirzepatide Products. January 2025.
11. U.S. v. Martinez. S.D. Fla. Case No. 24-CR-1847. 2024.
12. Davies MJ et al. Gastric Emptying and GLP-1 Receptor Agonists. Diabetes Care. 2023.
13. American College of Gastroenterology. GERD Management Guidelines. 2022.
14. North Carolina General Statutes § 90-18.2. Compounded Weight-Loss Medication Prescribing Requirements. Amended 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.